Dogwood Therapeutics, Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

Business Combination (Tables)

Business Combination (Tables)

9 Months Ended

Sep. 30, 2026

Business Combination

Schedule of fair value of consideration



Fair value of common stock issued		$	893,093
Fair value of preferred stock issued			70,372,634
Total Consideration Paid		$	71,265,727

Schedule of intangible assets acquired


											Carrying Value									Carrying Value
											as of									as of
		Combination Date									December 31									September 30,
		Fair Value			Impairment			Translation Adj			2025			Impairment			Translation Adj			2026
Halneuron® for Cancer Related Pain		$	59,900,000		$	—		$	(443,841)		$	59,456,159		$	—		$	(2,019,867)		$	57,436,292
Halneuron® for Chemotherapy Induced Neuropathic Pain			9,600,000			—			(71,133)			9,528,867			(9,190,897)			(337,970)			—
Total in-process research and development (IPR&D)		$	69,500,000		$	—		$	(514,974)		$	68,985,026		$	(9,190,897)		$	(2,357,837)		$	57,436,292

Goodwill		$	12,493,727		$	—		$	(92,609)		$	12,401,118		$	—		$	(421,295)		$	11,979,823

Tabular disclosure of business combination. Includes, but is not limited to, recognized asset and liability.

+ References + Details